Ginkgo Bioworks Holdings Inc
DNA8.405USD
-0.505-5.67%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
477.71MMarket Cap
LossP/E TTM
More Details of Ginkgo Bioworks Holdings Inc Company
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Ginkgo Bioworks Holdings Inc Info
Ticker SymbolDNA
Company nameGinkgo Bioworks Holdings Inc
IPO dateApr 19, 2021
CEOKelly (Jason)
Number of employees834
Security typeOrdinary Share
Fiscal year-endApr 19
Address27 Drydock Avenue
CityBOSTON
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code02210
Phone18774425362
Websitehttps://investors.ginkgobioworks.com/
Ticker SymbolDNA
IPO dateApr 19, 2021
CEOKelly (Jason)
Company Executives of Ginkgo Bioworks Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Harry Evans Sloan, J.D.
Mr. Harry Evans Sloan, J.D.
Independent Director
Independent Director
282.24K
+3.99%
Shyam Sankar
Shyam Sankar
Independent Chairman of the Board
Independent Chairman of the Board
83.19K
+14.95%
Dr. Sri Kosuri
Dr. Sri Kosuri
Independent Director
Independent Director
48.13K
+100.00%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Director
Independent Director
35.13K
-36.28%
Dr. Kathy Hopinkah Hannan
Dr. Kathy Hopinkah Hannan
Independent Director
Independent Director
25.82K
+72.13%
Mr. Ross Fubini
Mr. Ross Fubini
Independent Director
Independent Director
21.64K
+100.00%
Mr. Steven P. (Steve) Coen, CPA
Mr. Steven P. (Steve) Coen, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Reshma Shetty
Dr. Reshma Shetty
President, Chief Operating Officer, Director
President, Chief Operating Officer, Director
--
--
Dr. Jason Kelly
Dr. Jason Kelly
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Harry Evans Sloan, J.D.
Mr. Harry Evans Sloan, J.D.
Independent Director
Independent Director
282.24K
+3.99%
Shyam Sankar
Shyam Sankar
Independent Chairman of the Board
Independent Chairman of the Board
83.19K
+14.95%
Dr. Sri Kosuri
Dr. Sri Kosuri
Independent Director
Independent Director
48.13K
+100.00%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Director
Independent Director
35.13K
-36.28%
Dr. Kathy Hopinkah Hannan
Dr. Kathy Hopinkah Hannan
Independent Director
Independent Director
25.82K
+72.13%
Mr. Ross Fubini
Mr. Ross Fubini
Independent Director
Independent Director
21.64K
+100.00%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
37.20M
75.00%
Undetermined
12.40M
25.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Viking Global Investors LP
7.37%
Cascade Investment, L.L.C.
6.85%
Baillie Gifford & Co.
6.67%
BlackRock Institutional Trust Company, N.A.
6.32%
The Vanguard Group, Inc.
5.10%
Other
67.69%
Shareholders
Shareholders
Proportion
Viking Global Investors LP
7.37%
Cascade Investment, L.L.C.
6.85%
Baillie Gifford & Co.
6.67%
BlackRock Institutional Trust Company, N.A.
6.32%
The Vanguard Group, Inc.
5.10%
Other
67.69%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.83%
Investment Advisor/Hedge Fund
19.52%
Family Office
6.85%
Hedge Fund
5.30%
Research Firm
4.80%
Individual Investor
3.45%
Private Equity
1.26%
Sovereign Wealth Fund
0.81%
Bank and Trust
0.62%
Other
25.58%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
616
31.33M
82.97%
-3.08K
2025Q3
650
31.34M
86.08%
-3.02M
2025Q2
656
34.37M
83.97%
+457.02K
2025Q1
673
33.91M
82.69%
-3.97M
2024Q4
692
33.51M
68.84%
+6.17M
2024Q3
716
27.73M
60.45%
+3.82M
2024Q2
719
23.92M
77.75%
-7.88M
2024Q1
705
31.92M
79.75%
-995.74K
2023Q4
687
31.09M
80.11%
+570.00K
2023Q3
677
30.49M
78.26%
+524.01K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Viking Global Investors LP
3.58M
7.6%
--
--
Jun 30, 2025
Cascade Investment, L.L.C.
3.80M
8.06%
--
--
Apr 17, 2025
Baillie Gifford & Co.
3.28M
6.96%
-74.84K
-2.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.72M
5.79%
+1.70M
+166.85%
Jun 30, 2025
The Vanguard Group, Inc.
2.38M
5.04%
+250.12K
+11.77%
Jun 30, 2025
Erste Asset Management GmbH
2.00M
4.25%
+350.00K
+21.21%
Jun 30, 2025
Anchorage Capital Group, L.L.C.
1.75M
3.71%
--
--
Jun 30, 2025
Legal & General Investment Management Ltd.
1.49M
3.17%
+71.93K
+5.07%
Jun 30, 2025
BofA Global Research (US)
1.21M
2.56%
+199.81K
+19.84%
Jun 30, 2025
J.M. Forbes & Co. LLP
1.08M
2.29%
-17.32K
-1.58%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ROBO Global Artificial Intelligence ETF
1.55%
WisdomTree BioRevolution Fund
1.41%
iShares Genomics Immunology and Healthcare ETF
1.03%
US Vegan Climate ETF
0.13%
Inspire Small/Mid Cap ESG ETF
0.13%
AXS Green Alpha ETF
0.13%
Vanguard US Momentum Factor ETF
0.13%
iShares Micro-Cap ETF
0.1%
Invesco RAFI US 1500 Small-Mid ETF
0.07%
Avantis US Small Cap Equity ETF
0.05%
View more
ROBO Global Artificial Intelligence ETF
Proportion1.55%
WisdomTree BioRevolution Fund
Proportion1.41%
iShares Genomics Immunology and Healthcare ETF
Proportion1.03%
US Vegan Climate ETF
Proportion0.13%
Inspire Small/Mid Cap ESG ETF
Proportion0.13%
AXS Green Alpha ETF
Proportion0.13%
Vanguard US Momentum Factor ETF
Proportion0.13%
iShares Micro-Cap ETF
Proportion0.1%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.07%
Avantis US Small Cap Equity ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 05, 2024
Merger
40→1
Jul 05, 2024
Merger
40→1
Jul 05, 2024
Merger
40→1
Jul 05, 2024
Merger
40→1
Date
Type
Ratio
Jul 05, 2024
Merger
40→1
Jul 05, 2024
Merger
40→1
Jul 05, 2024
Merger
40→1
Jul 05, 2024
Merger
40→1
FAQs
Who are the top five shareholders of Ginkgo Bioworks Holdings Inc?
The top five shareholders of Ginkgo Bioworks Holdings Inc are:
Viking Global Investors LP holds 3.58M shares, accounting for 7.60% of the total shares.
Cascade Investment, L.L.C. holds 3.80M shares, accounting for 8.06% of the total shares.
Baillie Gifford & Co. holds 3.28M shares, accounting for 6.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.72M shares, accounting for 5.79% of the total shares.
The Vanguard Group, Inc. holds 2.38M shares, accounting for 5.04% of the total shares.
Viking Global Investors LP holds 3.58M shares, accounting for 7.60% of the total shares.
Cascade Investment, L.L.C. holds 3.80M shares, accounting for 8.06% of the total shares.
Baillie Gifford & Co. holds 3.28M shares, accounting for 6.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.72M shares, accounting for 5.79% of the total shares.
The Vanguard Group, Inc. holds 2.38M shares, accounting for 5.04% of the total shares.
What are the top three shareholder types of Ginkgo Bioworks Holdings Inc?
The top three shareholder types of Ginkgo Bioworks Holdings Inc are:
Viking Global Investors LP
Cascade Investment, L.L.C.
Baillie Gifford & Co.
Viking Global Investors LP
Cascade Investment, L.L.C.
Baillie Gifford & Co.
How many institutions hold shares of Ginkgo Bioworks Holdings Inc (DNA)?
As of 2025Q4, 616 institutions hold shares of Ginkgo Bioworks Holdings Inc, with a combined market value of approximately 31.33M, accounting for 82.97% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.11%.
What is the biggest source of revenue for Ginkgo Bioworks Holdings Inc?
In FY2025Q2, the -- business generated the highest revenue for Ginkgo Bioworks Holdings Inc, amounting to -- and accounting for --% of total revenue.
